Lymphoma News Poster Sessions

Abstract 7516 Poster Discussion Session; Displayed in Poster Session (Board #153),

Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL. First Author: David Andorsky, Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO

Conclusions: R2 therapy showed favorable activity and tolerable safety profiles in patients who had R/R FL and MZL, regardless of the number of prior anti-lymphoma therapies. Enrollment in MAGNIFY is ongoing. Clinical trial information: NCT01996865

Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST). First Author: Grzegorz S. Nowakowski, Mayo Clinic, Rochester, MN

Conclusions: Real-time COO assessment was feasible from multiple regions globally with a short turnaround time in the phase III ROBUST study, which minimizes the delay in receiving treatment. The percent of ABC-type DLBCL was similar to other reported studies of subtype analysis in the literature. Our findings impact the design and size estimation of future studies in newly diagnosed DLBCL utilizing COO as a biomarker, which provides a significant advance in precision medicine in DLBCL. Clinical trial information: NCT02285062. Abstract 7548


Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process. First Author: Peihua Lu, Hebei Yanda Lu Daopei Hospital, Langfang, China

Conclusions: The study illustrates that 4-1BB CAR-T cells show enhanced safety, efficacy, and expansion than CD28 CAR-T cells, suggesting a superior therapeutic strategy in the treatment of relapsed or refractory CD19-positive B-ALL patients. Clinical trial information: NCT03173417. Abstract 3041